SORD

Across TCGA pan-cancer cohorts, SORD mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SORD data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SORD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SORD expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where SORD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.661	0.403	<.001	74	view →
CCRCC	OS	Median	II,III,IV	0.950	0.677	.002	44	view →
LSCC	OS	Tertile	All	0.882	0.709	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SORD–PDAC (OS)

Open the PDAC breakdown →